Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey
- 31 May 2004
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 23 (5) , 510-512
- https://doi.org/10.1016/j.ijantimicag.2003.09.029
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Linezolid Treatment of Prosthetic Hip Infections due to Methicillin-resistant Staphylococcus aureus (MRSA)Journal of Infection, 2001
- Quinupristin-Dalfopristin Resistance among Gram-Positive Bacteria in TaiwanAntimicrobial Agents and Chemotherapy, 2000
- In Vitro Activities of Linezolid against Important Gram-Positive Bacterial Pathogens Including Vancomycin-Resistant EnterococciAntimicrobial Agents and Chemotherapy, 1999
- Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compoundsDiagnostic Microbiology and Infectious Disease, 1999
- Antimicrobial Activity of Gatifloxacin Tested Against 1676 Gram-Positive Cocci Resistant to CiprofloxacinDrugs, 1999
- Antimicrobial Activity of Quinupristin-Dalfopristin (RP 59500, Synercid®) Tested against Over 28,000 Recent Clinical Isolates from 200 Medical Centers in the United States and CanadaDiagnostic Microbiology and Infectious Disease, 1998
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997